Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938256 | 0.92 | MLYCD (0.32) | MLYCD | |
| SCHEMBL19299845 | 0.91 | MLYCD (0.37) | MLYCDLMNAMEN1KMT2AMMP1 | |
| SCHEMBL13915080 | 0.81 | — | — | |
| SCHEMBL13915136 | 0.79 | KDM4E (0.43) | MEN1KMT2A | |
| SCHEMBL13915081 | 0.78 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL13915116 | 0.77 | — | — | |
| SCHEMBL13915119 | 0.77 | MLYCD (0.32) | MLYCDMEN1KMT2A | |
| SCHEMBL249531 | 0.74 | MLYCD (0.45) | MLYCDLMNAMEN1KMT2AMMP1 | |
| SCHEMBL23618253 | 0.74 | MLYCD (0.33) | MLYCDLMNA | |
| SCHEMBL21235948 | 0.72 | MLYCD (0.39) | MLYCDLMNAMEN1KMT2AMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227610-B2 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques | CARNEGIE MELLON UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090074673-A1 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques | CARNEGIE MELLON UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074673-A1 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques | NES, MKI67, CD68 | MLYCD 1269/4885LMNA 130/4885MEN1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.